Recent Finacing
Recent Raise
Savara Pharmaceuticals develops inhaled pulmonary therapeutics—dry‑powder vancomycin AeroVanc for MRSA in cystic fibrosis, MOLBREEVI for autoimmune pulmonary alveolar proteinosis, and NanoCluster formulation technology.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Savara Pharmaceuticals.
